Skip to main content

19-10-2020 | Gastroenterology | Video

UEGW 2020 | Filgotinib shows efficacy as induction therapy for moderate to severe UC

Brian Feagan shares the SELECTION study findings showing a role for filgotinib in the treatment of biologic-naive and experienced patients with moderately to severely active ulcerative colitis (10:21).

Funding for independent interviews at UEG Week Virtual 2020 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.